Assembly Biosciences Inc ASMB.OQ ASMB.O is expected to show a rise in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
The South San Francisco California-based company is expected to report a 9.0% increase in revenue to $7.459 million from $6.85 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Assembly Biosciences Inc is for a loss of 77 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Assembly Biosciences Inc is $38.00, about 18.3% above its last closing price of $31.05
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -1.19 | -1.36 | -1.33 | Beat | 2.6 |
Mar. 31 2025 | -1.60 | -1.60 | -1.17 | Beat | 26.9 |
Dec. 31 2024 | -2.04 | -1.57 | Beat | 23 | |
Sep. 30 2024 | -2.02 | -2.02 | -1.51 | Beat | 25.2 |
Jun. 30 2024 | -2.23 | -2.23 | -1.98 | Beat | 11.2 |
Mar. 31 2024 | -3.23 | -3.23 | -1.66 | Beat | 48.6 |
Dec. 31 2023 | -2.88 | -2.15 | Beat | 25.3 | |
Sep. 30 2023 | -2.76 | -3.24 | Missed | -17.4 |
This summary was machine generated November 3 at 23:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)